Agilent Technologies' OneSeq

Agilent Technologies has launched OneSeq, an all-in-one target enrichment product for next-generation sequencing. OneSeq is designed to detect and analyze copy number variations, loss of heterozygosity, and mutations in a single reaction for use in constitutional disease research. Powered by the company's SureSelect target enrichment platform, OneSeq will help laboratories involved in cytogenetic research save time gathering and analyzing complex, multifactorial data, Agilent said.

Agilent showcased the technology at the Advances in Genome Biology and Technology conference in Marco Island, Fla., this week.